Trial Profile
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX B/E in Healthy, HIV Uninfected Adult Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs DNA HIV PT123 (Primary) ; HIV gp120 vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 12 Apr 2016 Status changed from active, no longer recruiting to completed.
- 26 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 07 Aug 2014 New trial record